The trauma products market is expected to reach USD 8.43 billion by 2022 from USD 5.98 billion in 2017, at a CAGR of 7.1% during the forecast period. Factors such as growth in geriatric population, the high prevalence of bone degenerative diseases, increasing incidence of road accidents & falls, and increasing sports injuries are driving the demand for trauma products.
Mergers & acquisitions accounted for the largest share of the overall growth strategy mapped from 2014–2017. Some of the leading players who adopted this strategy include DePuy Synthes (U.S.) and Zimmer Biomet Holding Inc. (U.S.).
Download PDF Brochure Here : http://www.marketsandmarkets.com/pdfdownload.asp?id=213911560
The trauma products market is highly competitive with several big and small players. Prominent players in the trauma product market include DePuy Synthes (U.S.), Stryker (U.S.), Zimmer Biomet Holding Inc. (U.S.), and Smith & Nephew (U.K.). Other players include Accumed LLC (U.S.), Arthrex Inc. (U.S.), B. Braun Melsungen AG (Germany), Cardinal Health (U.S.), Citieffe S.R.L. (Italy), Conmed Corporation (U.S.), Double Medical Inc. (China), Integra LifeSciences Corporation (U.S.), Medtronic plc (Ireland), Orthofix Holdings Inc. (U.S.), and Wright Medical Group N.V. (U.S.).
In 2016, DePuy Synthes dominated the trauma products market. The company has managed to create its identity in this market due to its robust product portfolio and large geographic presence. In addition, the company also focuses on inorganic growth strategies like acquisitions and agreements. For instance, in 2016, the company acquired BioMedical Enterprises, Inc. (U.S.), a manufacturer of Nitinol orthopaedic implants for small bone fixation. The company also focuses on continuous product developments to maintain its leading position in the market. For instance, in March 2015, the company launched the TFN-ADVANCED Proximal Femoral Nailing System (TFNA) for hip fracture surgery.
Stryker Corporation was the second leading player in the trauma products market in 2016. The company adopted inorganic growth strategies such as collaborations, acquisitions, and agreements to strengthen its product portfolio as well as its market position. In 2016, the company collaborated with the Indo U.K. Institutes of Health (India) to provide Indian customers with orthopedic and trauma products. In 2016, the company acquired Stanmore Implants Worldwide Ltd. (U.K.), a manufacturer of implants to strengthen its position in the global market. Furthermore, in 2014, the company signed an agreement with Small Bone Innovations, Inc. (“SBi”) (U.S.) to strengthen its product portfolio in the orthopedic segment. Also, continuous innovation and R&D helps the company maintain its position in the market.
